Resources from the same session
Safety and Efficacy of Pembrolizumab (Pembro) Monotherapy in Elderly Patients (Pts) With PD-L1–positive Advanced NSCLC: Pooled Analysis from KEYNOTE-010, -024, and -042
Presenter: Kaname Nosaki
Session: ESMO-IASLC Best Abstracts
Resources:
Abstract
Presentation
Webcast
Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): results from the double-blind, randomized phase 3 CheckMate 451 study
Presenter: Taofeek Owonikoko
Session: ESMO-IASLC Best Abstracts
Resources:
Abstract
Presentation
Webcast
Invited Discussant 102O and 103O
Presenter: Sanjay Popat
Session: ESMO-IASLC Best Abstracts
Resources:
Presentation
Webcast
Final Analysis of the Phase 3 KEYNOTE-042 Study: Pembrolizumab (Pembro) Versus Platinum-Based Chemotherapy (Chemo) as First-Line Therapy for Patients (Pts) With PD-L1–Positive Locally Advanced/Metastatic NSCLC
Presenter: Tony S.K. Mok
Session: ESMO-IASLC Best Abstracts
Resources:
Abstract
Presentation
Webcast
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: results from MYSTIC
Presenter: Byoung Chul Cho
Session: ESMO-IASLC Best Abstracts
Resources:
Abstract
Presentation
Webcast